LivaNova Permitted to Modify Cardiopulmonary Products’ Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19
Various products can now be used to treat patients experiencing acute respiratory or cardiopulmonary failure LONDON--(BUSINESS WIRE)--$LIVN--LivaNova PLC (NASDAQ:LIVN), a...